Beijing, Nov. 12, 2020 – Keya Medical Technology Co., Ltd. (Keya Medical), a leader in medical AI technology development, announced that it has completed a $30 Million Series C funding round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
This investment is the third large-scale funding round that Keya Medical has completed in just nine months. In February, Keya Medical received a strategic investment led by Kunlun Internet Smart Fund, and a joint co-investment by Growth FOF, and Alwin Capital. In August, Keya Medical was awarded an additional $22 million in a Series B+ funding round.
Despite the impact of the COVID-19 pandemic, Keya Medical has continued to accelerate progress in medical AI. The company’s flagship product, DEEPVESSEL FFR, became the first AI software medical device to receive National Medical Products Administration approval in January, and is the only CT-derived FFR product approved for clinical use in China. Keya Medical has adhered to the product development principle of developing solutions that are based on “real clinical needs,” using funds to bring products to market that empower both clinicians and patients.
About Keya Medical
Keya Medical Technology Co. Ltd. is a medical technology manufacturer that develops artificial intelligence applications that enable healthcare delivery organizations to provide better patient care. Since 2016, the company has combined advanced deep learning algorithms with other technologies to provide accurate diagnosis and treatment solutions to medical institutions around the world. Today, Keya Medical has partnered with over 200 healthcare systems around the world, and the company’s products are used in Chinese hospitals, coronary catheterization labs, and imaging centers. To learn more about Keya Medical, follow us on LinkedIn and Twitter.